It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Once a week, Sun Kai has a video call with his mother, and they discuss his day-to-day life. But Sun’s mother died five years ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

Unlocking Plastic Recycling Since their widespread adoption by the manufacturing industry in the 1960s, plastics have become an omnipresent material in our daily lives. They are also the cause of very ...

Researchers at Beijing's Chinese Academy of Sciences have used the gene-editing technology CRISPR to create mice from two ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned ...

The CRISPR technology market is poised for explosive ... designation, which speeds up review times and offers additional support to developers. Similarly, Europe has made strides with its ...

In a groundbreaking study, scientists from China have successfully created mice with two biological fathers. Though the ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...